Provided by Tiger Trade Technology Pte. Ltd.

Vanguard Health Care ETF

316.08
-3.7100-1.16%
Post-market: 316.250.1700+0.05%19:57 EDT
Volume:231.18K
Turnover:73.56M
Market Cap:19.02B
PE:34.31
High:320.01
Open:319.37
Low:316.08
Close:319.79
52wk High:330.75
52wk Low:260.42
Shares:60.18M
Float Shares:60.18M
Volume Ratio:1.38
T/O Rate:0.38%
Dividend:4.62
Dividend Rate:1.46%
EPS(TTM):9.21
EPS(LYR):41.51
ROE:3.75%
ROA:0.89%
PB:0.96
PE(LYR):7.61

Loading ...

Spyre Gains After Merck's Drug Succeeds in Skin Disease Trial

Reuters
·
Yesterday

Eli Lilly Reports 'Positive' Results From EloraTZP Trial

MT Newswires Live
·
Yesterday

Weight-Loss Drug Developers Line up to Tap Lucrative Market as Competition Heats Up

Reuters
·
Yesterday

Adding Lilly's New Drug to Zepbound Helped People Lose up to 23% of Their Weight. but There were More Side Effects.

Dow Jones
·
Yesterday

Eli Lilly Says EloraTZP Combo Delivered 'Substantial' Weight Loss, A1C Reduction in Phase 2b Trial

MT Newswires Live
·
Yesterday

Lilly says participants on EloraTZP lost up to average 23.3% of weight in study

TIPRANKS
·
Yesterday

Lilly's Eloratzp (Combination of Eloralintide and Tirzepatide) Delivered Greater Weight Loss and A1c Reduction VS. Tirzepatide 15 Mg in Adults with Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Yesterday

Eli Lilly: Plans to Initiate Phase 3 Studies of Eloratzp Co-Formulation Product by 2026 End Using Optimized Escalation Schedule

THOMSON REUTERS
·
Yesterday

Eli Lilly: at 48 Weeks, All Combinations of Eloratzp Met Primary & Secondary Endpoints

THOMSON REUTERS
·
Yesterday

Experimental Lilly Combination Drug Tops Zepbound in Weight-Loss Trial

Reuters
·
Yesterday

Eli Lilly: Participants Taking Eloratzp Lost up to Average of 54.1 Lbs (23.3%) VS. 34.4 Lbs (14.8%) with Tirzepatide 15 Mg

THOMSON REUTERS
·
Yesterday

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Amid Inflation Data Release

MT Newswires Live
·
Yesterday

Merck Says Experimental Skin Disease Drug Meets Main Goal in Mid-Stage Study

Reuters
·
Yesterday

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Yesterday

Merck Says Tulisokibart Hits Primary Endpoint in Phase 2b Hidradenitis Suppurativa Trial

Reuters
·
Yesterday

Merck & Co - Study Meets Primary Endpoint Hiscr50 at Week 16 for High- and Medium-Dose Tulisokibart

THOMSON REUTERS
·
Yesterday

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2B Study in Patients with Moderate to Severe Hidradenitis Suppurativa (Hs)

THOMSON REUTERS
·
Yesterday

Merck & Co - no Serious or Opportunistic Infections Observed in Study

THOMSON REUTERS
·
Yesterday

Lilly Says Phase 3b ADtouch Trial Shows Ebglyss Beats Placebo in Hand and Foot Atopic Dermatitis Skin Clearance at Week 16

Reuters
·
Yesterday

Eli Lilly - 77% of Ebglyss Patients Reported Satisfaction with Hand Clearance at Week 16

THOMSON REUTERS
·
Yesterday